\-\ Texto\\:\\ \ \(0\)\
\-\ not\\ available\\.\ \(14\)\
\-\ serum\\ calcium\\ concentrations\\ must\\ be\\ periodically\\ and\\ carefully\\ monitored\\.\\ \\ phosphorus\\ replacement\\ and\\ vitamin\\ d\\ replacement\\ with\\ calcitriol\\ are\\ used\\ as\\ the\\ mainstays\\ of\\ treatment\\.\\ \\ amiloride\\ and\\ hydrochlorothiazide\\ are\\ also\\ administered\\ to\\ enhance\\ calcium\\ reabsorption\\ and\\ to\\ reduce\\ the\\ risk\\ of\\ nephrocalcinosis\\.\ \(0\)\
\-\ sonographic\\ images\\ through\\ both\\ kidneys\\ demonstrate\\ multiple\\ areas\\ of\\ increased\\ echogenicity\\ involving\\ the\\ medullary\\ pyramids\\.\\ the\\ remaining\\ renal\\ cortex\\ is\\ normal\\ in\\ echogenicity\\.\\ there\\ is\\ no\\ evidence\\ of\\ hydronephrosis\\ or\\ focal\\ mass\\ lesions\\.\ \(0\)\
\-\ medullary\\ nephrocalcinosis\\ secondary\\ to\\ hypophosphatemic\\ rickets\ \(0\)\
\-\ causes\\ of\\ medullary\\ nephrocalcinosis\\:\ \(1\)\
\-\ hyperparathyroidism\ \(35\)\
\-\ hypercalciuria\ \(4\)\
\-\ hypercalcemia\ \(21\)\
\-\ medullary\\ sponge\\ kidney\ \(4\)\
\-\ renal\\ tubular\\ acidosis\ \(5\)\
\-\ milk\\-alkali\\ syndrome\ \(0\)\
\-\ cushing\\ syndrome\ \(0\)\
\-\ bony\\ metastases\ \(2\)\
\-\ hyperthyroidism\ \(31\)\
\-\ hypothyroidism\ \(39\)\
\-\ sarcoidosis\ \(108\)\
\-\ furosemide\\ therapy\ \(0\)\
\-\ vitamin\\ d\\ and\\ phosphorus\\ therapy\\ in\\ hypophosphatemic\\ rickets\ \(0\)\
\-\ this\\ nine\\ year\\ old\\ boy\\ presents\\ with\\ a\\ history\\ of\\ hypophosphatemic\\ rickets\\.\ \(0\)\
\-\ x\\-linked\\ hypophosphatemic\\ rickets\\ is\\ a\\ congenital\\ metabolic\\ bone\\ disease\\ produced\\ by\\ a\\ urinary\\ phosphate\\ leak\\.\\ \\ vitamin\\ d\\ and\\ oral\\ phosphate\\ supplementation\\ therapy\\ is\\ useful\\ in\\ the\\ treatment\\ of\\ this\\ disease\\.\\ \\ medullary\\ nephrocalcinosis\\ may\\ occur\\ in\\ 33\\ to\\ 50\\%\\ of\\ patients\\ with\\ x\\-linked\\ hypophosphatemic\\ rickets\\ treated\\ with\\ vitamin\\ d\\ and\\ phosphate\\ therapy\\.\\ \\ the\\ medullary\\ nephrocalcinosis\\ is\\ due\\ to\\ hypercalcemia\\ and\\ hypercalciuria\\ resulting\\ from\\ the\\ treatment\\.\\ \\ the\\ treatment\\ and\\ medullary\\ nephrocalcinosis\\ alone\\ have\\ not\\ been\\ associated\\ with\\ impaired\\ renal\\ function\\.\\ \\ however\\,\\ if\\ secondary\\ hyperparathyroidism\\ develops\\,\\ increased\\ medullary\\ and\\ cortical\\ echogenicity\\ may\\ be\\ seen\\ with\\ impaired\\ renal\\ function\\.\\ \\ \ \(0\)\
\-\ references\\:\ \(0\)\
\-\ 1\\.\\ \\ middleton\\ wd\\,\\ kurtz\\ ab\\,\\ hertzberg\\ bs\\.\\ \\ ultrasound\\:\\ the\\ requisites\\.\\ 2nd\\ ed\\.\\ \\ st\\.\\ louis\\,\\ mo\\:\\ mosby\\,\\ inc\\.\\ 2004\\:\\ 136\\.\ \(0\)\
\-\ 2\\.\\ \\ brant\\ we\\.\\ \\ the\\ core\\ curriculum\\.\\ ultrasound\\.\\ philadelphia\\,\\ pa\\:\\ lippincott\\ williams\\ \\&\\ wilkins\\.\\ 2001\\:\\ 115\\.\ \(0\)\
\-\ 3\\.\\ \\ townsend\\ rr\\,\\ et\\ al\\.\\ \\ acr\\ ultrasound\\ cd\\-rom\\ series\\ learning\\ file\\.\\ \\ 2nd\\ ed\\.\\ \\ reston\\,\\ virginia\\:\\ american\\ college\\ of\\ radiology\\.\\ 2003\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hypophosphatemic\\:\\ 0\\.1360419509871373\ \(0\)\
\-\ nephrocalcinosis\\:\\ 0\\.11078342740574595\ \(0\)\
\-\ medullary\\:\\ 0\\.10138242525072011\ \(0\)\
\-\ rickets\\:\\ 0\\.08304832128829247\ \(0\)\
\-\ vitamin\\:\\ 0\\.062115170247509094\ \(0\)\
\-\ phosphate\\:\\ 0\\.05942243658489007\ \(0\)\
\-\ d\\:\\ 0\\.052612858424271075\ \(0\)\
\-\ hypercalciuria\\:\\ 0\\.04585940779534943\ \(0\)\
\-\ echogenicity\\:\\ 0\\.042555654803614736\ \(0\)\
\-\ x\\-linked\\:\\ 0\\.04085366571993999\ \(0\)\
\-\ phosphorus\\:\\ 0\\.03961495772326005\ \(0\)\
\-\ hypercalcemia\\:\\ 0\\.035336271423507294\ \(0\)\
\-\ impaired\\:\\ 0\\.03407210838248252\ \(0\)\
\-\ renal\\:\\ 0\\.03169722900565517\ \(0\)\
\-\ therapy\\:\\ 0\\.028205441928896454\ \(0\)\
\-\ \\:\\:\\ 0\\.027908020147917652\ \(0\)\
\-\ hyperparathyroidism\\:\\ 0\\.0276838585412356\ \(0\)\
\-\ amiloride\\:\\ 0\\.027208390197427462\ \(0\)\
\-\ kurtz\\:\\ 0\\.027208390197427462\ \(0\)\
\-\ hertzberg\\:\\ 0\\.027208390197427462\ \(0\)\
\-\ cd\\-rom\\:\\ 0\\.027208390197427462\ \(0\)\
\-\ reston\\:\\ 0\\.027208390197427462\ \(0\)\
\-\ 2nd\\:\\ 0\\.026306429212135538\ \(0\)\
\-\ calcium\\:\\ 0\\.025807342195906555\ \(0\)\
\-\ replacement\\:\\ 0\\.025747700770525468\ \(0\)\
\-\ calcitriol\\:\\ 0\\.02506904704755109\ \(0\)\
\-\ curriculum\\:\\ 0\\.02506904704755109\ \(0\)\
\-\ townsend\\:\\ 0\\.02506904704755109\ \(0\)\
\-\ mainstays\\:\\ 0\\.02381761152869873\ \(0\)\
\-\ ultrasound\\:\\ 0\\.02347335726857688\ \(0\)\
\-\ hydrochlorothiazide\\:\\ 0\\.022929703897674715\ \(0\)\
\-\ milk\\-alkali\\:\\ 0\\.022929703897674715\ \(0\)\
\-\ virginia\\:\\ 0\\.022929703897674715\ \(0\)\
\-\ function\\:\\ 0\\.022361491191828935\ \(0\)\
\-\ ed\\:\\ 0\\.022293282326479646\ \(0\)\
\-\ reabsorption\\:\\ 0\\.022240989233124682\ \(0\)\
\-\ wd\\:\\ 0\\.021678268378822352\ \(0\)\
\-\ treatment\\:\\ 0\\.021353295797541815\ \(0\)\
\-\ middleton\\:\\ 0\\.021202494675651804\ \(0\)\
\-\ acr\\:\\ 0\\.021202494675651804\ \(0\)\
\-\ learning\\:\\ 0\\.021202494675651804\ \(0\)\
\-\ periodically\\:\\ 0\\.020790360747798338\ \(0\)\
\-\ furosemide\\:\\ 0\\.020790360747798338\ \(0\)\
\-\ 136\\:\\ 0\\.020790360747798338\ \(0\)\
\-\ concentrations\\:\\ 0\\.020426832859969993\ \(0\)\
\-\ 115\\:\\ 0\\.020426832859969993\ \(0\)\
\-\ file\\:\\ 0\\.02010164608324831\ \(0\)\
\-\ cushing\\:\\ 0\\.019807478861630024\ \(0\)\
\-\ supplementation\\:\\ 0\\.019807478861630024\ \(0\)\
\-\ pyramids\\:\\ 0\\.01906315152577543\ \(0\)\
\-\ brant\\:\\ 0\\.01906315152577543\ \(0\)\
\-\ college\\:\\ 0\\.01906315152577543\ \(0\)\
\-\ carefully\\:\\ 0\\.018463904567624326\ \(0\)\
\-\ sponge\\:\\ 0\\.018463904567624326\ \(0\)\
\-\ nine\\:\\ 0\\.01812061557037055\ \(0\)\
\-\ ab\\:\\ 0\\.017811716006923068\ \(0\)\
\-\ louis\\:\\ 0\\.017811716006923068\ \(0\)\
\-\ inc\\:\\ 0\\.017399582079069605\ \(0\)\
\-\ st\\:\\ 0\\.017273588268821905\ \(0\)\
\-\ acidosis\\:\\ 0\\.01703605419124126\ \(0\)\
\-\ hyperthyroidism\\:\\ 0\\.01703605419124126\ \(0\)\
\-\ requisites\\:\\ 0\\.01703605419124126\ \(0\)\
\-\ bs\\:\\ 0\\.01660966425765849\ \(0\)\
\-\ mo\\:\\ 0\\.01660966425765849\ \(0\)\
\-\ lippincott\\:\\ 0\\.01660966425765849\ \(0\)\
\-\ wilkins\\:\\ 0\\.016148146560217246\ \(0\)\
\-\ develops\\:\\ 0\\.015981272420494175\ \(0\)\
\-\ monitored\\:\\ 0\\.015901101166163122\ \(0\)\
\-\ leak\\:\\ 0\\.01582295978349556\ \(0\)\
\-\ mosby\\:\\ 0\\.015528792561877273\ \(0\)\
\-\ williams\\:\\ 0\\.015528792561877273\ \(0\)\
\-\ hypothyroidism\\:\\ 0\\.015459431895667217\ \(0\)\
\-\ administered\\:\\ 0\\.015196599153876146\ \(0\)\
\-\ syndrome\\:\\ 0\\.015085843066263219\ \(0\)\
\-\ reduce\\:\\ 0\\.014896711041364887\ \(0\)\
\-\ produced\\:\\ 0\\.014896711041364887\ \(0\)\
\-\ philadelphia\\:\\ 0\\.01478446522602268\ \(0\)\
\-\ secondary\\:\\ 0\\.014747098558696341\ \(0\)\
\-\ core\\:\\ 0\\.01462339808660734\ \(0\)\
\-\ alone\\:\\ 0\\.014277357043024913\ \(0\)\
\-\ 2004\\:\\ 0\\.014185218267871577\ \(0\)\
\-\ 2001\\:\\ 0\\.014008803410340873\ \(0\)\
\-\ we\\:\\ 0\\.013882809600093172\ \(0\)\
\-\ useful\\:\\ 0\\.013761758016286749\ \(0\)\
\-\ remaining\\:\\ 0\\.013722440035492212\ \(0\)\
\-\ 33\\:\\ 0\\.013683616633619186\ \(0\)\
\-\ rr\\:\\ 0\\.013460404715163549\ \(0\)\
\-\ hydronephrosis\\:\\ 0\\.013285984313116199\ \(0\)\
\-\ 2003\\:\\ 0\\.01325225261394277\ \(0\)\
\-\ series\\:\\ 0\\.013120895779316858\ \(0\)\
\-\ metabolic\\:\\ 0\\.013025921524172557\ \(0\)\
\-\ increased\\:\\ 0\\.012904227048146023\ \(0\)\
\-\ sonographic\\:\\ 0\\.012786078979952443\ \(0\)\
\-\ enhance\\:\\ 0\\.012757367891488514\ \(0\)\
\-\ serum\\:\\ 0\\.012728921425115293\ \(0\)\
\-\ american\\:\\ 0\\.012563537949392741\ \(0\)\
\-\ tubular\\:\\ 0\\.012281594188317963\ \(0\)\
\-\ urinary\\:\\ 0\\.01220896919631119\ \(0\)\
\-\ kidneys\\:\\ 0\\.01213801389314854\ \(0\)\
\-\ must\\:\\ 0\\.012023263883143127\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.011912627673966782\ \(0\)\
\-\ resulting\\:\\ 0\\.011583096885615837\ \(0\)\
\-\ may\\:\\ 0\\.011569928203074838\ \(0\)\
\-\ cortex\\:\\ 0\\.011285380014666571\ \(0\)\
\-\ metastases\\:\\ 0\\.011267692747046247\ \(0\)\
\-\ al\\:\\ 0\\.011180745595914468\ \(0\)\
\-\ radiology\\:\\ 0\\.011146641163239823\ \(0\)\
\-\ oral\\:\\ 0\\.011112909464066395\ \(0\)\
\-\ pa\\:\\ 0\\.011030158669465603\ \(0\)\
\-\ references\\:\\ 0\\.010965519244017322\ \(0\)\
\-\ et\\:\\ 0\\.010794439599142844\ \(0\)\
\-\ bony\\:\\ 0\\.01054739420508872\ \(0\)\
\-\ causes\\:\\ 0\\.010267224375956207\ \(0\)\
\-\ used\\:\\ 0\\.01011785233625914\ \(0\)\
\-\ 50\\:\\ 0\\.01003394449581421\ \(0\)\
\-\ occur\\:\\ 0\\.009895205644387464\ \(0\)\
\-\ congenital\\:\\ 0\\.009645552375439622\ \(0\)\
\-\ cortical\\:\\ 0\\.009614428551159912\ \(0\)\
\-\ risk\\:\\ 0\\.009553106936293475\ \(0\)\
\-\ kidney\\:\\ 0\\.009291306960030894\ \(0\)\
\-\ \\&\\:\\ 0\\.009263542876979726\ \(0\)\
\-\ involving\\:\\ 0\\.009254343407417572\ \(0\)\
\-\ 3\\.\\:\\ 0\\.009024303123891133\ \(0\)\
\-\ boy\\:\\ 0\\.008965190678783862\ \(0\)\
\-\ areas\\:\\ 0\\.00887452830631502\ \(0\)\
\-\ available\\:\\ 0\\.008866416817406781\ \(0\)\
\-\ is\\:\\ 0\\.008677326826924778\ \(0\)\
\-\ disease\\:\\ 0\\.008621836674171013\ \(0\)\
\-\ 2\\.\\:\\ 0\\.00838717327716129\ \(0\)\
\-\ 1\\.\\:\\ 0\\.008238238167585187\ \(0\)\
\-\ be\\:\\ 0\\.008134300761382279\ \(0\)\
\-\ treated\\:\\ 0\\.007894601345937837\ \(0\)\
\-\ not\\:\\ 0\\.00762233747988849\ \(0\)\
\-\ focal\\:\\ 0\\.007532387667093833\ \(0\)\
\-\ \\,\\:\\ 0\\.007519724042146871\ \(0\)\
\-\ through\\:\\ 0\\.007490608081545891\ \(0\)\
\-\ however\\:\\ 0\\.007343728566657624\ \(0\)\
\-\ are\\:\\ 0\\.007190579460059269\ \(0\)\
\-\ been\\:\\ 0\\.007175292868716022\ \(0\)\
\-\ if\\:\\ 0\\.007156615536359986\ \(0\)\
\-\ lesions\\:\\ 0\\.007060371933160332\ \(0\)\
\-\ due\\:\\ 0\\.007037892447385307\ \(0\)\
\-\ evidence\\:\\ 0\\.006914946244959499\ \(0\)\
\-\ patients\\:\\ 0\\.006825847528907487\ \(0\)\
\-\ both\\:\\ 0\\.006735185156438646\ \(0\)\
\-\ to\\:\\ 0\\.00659055722905843\ \(0\)\
\-\ bone\\:\\ 0\\.006553810745246511\ \(0\)\
\-\ associated\\:\\ 0\\.006223649882431178\ \(0\)\
\-\ \\%\\:\\ 0\\.006152225411561752\ \(0\)\
\-\ demonstrate\\:\\ 0\\.006069296732509385\ \(0\)\
\-\ this\\:\\ 0\\.005932945761198352\ \(0\)\
\-\ have\\:\\ 0\\.005711228636929295\ \(0\)\
\-\ and\\:\\ 0\\.005555833510253656\ \(0\)\
\-\ multiple\\:\\ 0\\.005554956800861941\ \(0\)\
\-\ presents\\:\\ 0\\.005387791035518289\ \(0\)\
\-\ seen\\:\\ 0\\.00521181362675213\ \(0\)\
\-\ in\\:\\ 0\\.005202434940003147\ \(0\)\
\-\ also\\:\\ 0\\.005199443190339973\ \(0\)\
\-\ images\\:\\ 0\\.005059456456633808\ \(0\)\
\-\ by\\:\\ 0\\.004391576861866897\ \(0\)\
\-\ the\\:\\ 0\\.004266953231593389\ \(0\)\
\-\ normal\\:\\ 0\\.00413460634135525\ \(0\)\
\-\ as\\:\\ 0\\.003989436746586814\ \(0\)\
\-\ there\\:\\ 0\\.003925048013780829\ \(0\)\
\-\ from\\:\\ 0\\.003908752201093248\ \(0\)\
\-\ a\\:\\ 0\\.0036722203872092706\ \(0\)\
\-\ mass\\:\\ 0\\.0036680895276159395\ \(0\)\
\-\ history\\:\\ 0\\.003642637462058899\ \(0\)\
\-\ \\.\\:\\ 0\\.003286994083087618\ \(0\)\
\-\ of\\:\\ 0\\.0032362166888330116\ \(0\)\
\-\ or\\:\\ 0\\.0030911195955669983\ \(0\)\
\-\ year\\:\\ 0\\.0029509421891139344\ \(0\)\
\-\ old\\:\\ 0\\.002700415422414366\ \(0\)\
\-\ no\\:\\ 0\\.0026556918231598827\ \(0\)\
\-\ with\\:\\ 0\\.0021667440016646246\ \(0\)\
